Search | TVST | ARVO Journals

Showing 1 – 19 of 19

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

Safety and expression following subretinal administration of AAV.ABCA4.intein vectors in the non-human primate retina

Bart Peter Leroy; Rita Ferla; Naveed Shams; Muhammad Ali Memon; Alberto Auricchio

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):6097.

Clinical Trials December 2021

Safety and Tolerability of Intravitreal Carotuximab (DE-122) in Patients With Persistent Exudative Age-Related Macular Degeneration: A Phase I Study

PDF

Victor H. Gonzalez; Brian Berger; Roger Goldberg; Carmelina M. Gordon; Rahul N. Khurana; Raymund Angeles; Naveed Shams
TAGS: anti-vascular endothelial growth factor therapy, exudative age-related macular degeneration, persistence, phase 1 clinical trials, safety, intravitreal injections, cohort studies, endoglin, eye
Trans. Vis. Sci. Tech.. 2021; 10(14):27. https://doi.org/10.1167/tvst.10.14.27

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2020

A randomized Phase 2 trial assessing the safety and efficacy of omidenepag isopropyl 0.002% once and twice daily in subjects with primary open-angle glaucoma or ocular hypertension (Spectrum 6)

Kenneth Olander; Michelle A Sato; Marc A Abrams; Gary W Jerkins; Fenghe Lu; Phillip Dinh; NORIKO ODANI; Almira Chabi; Naveed Kamal Shams

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4258.

ARVO Annual Meeting Abstract July 2019

Effects of Omidenepag Isopropyl, a Selective EP2 Receptor Agonist, on Iris Pigmentation

Yoshihiko Esaki; Takazumi Taniguchi; Ryo Iwamura; Kenji Yoneda; Noriko Odani-Kawabata; Hidetoshi Mano; Takeshi Matsugi; Naveed Kamal Shams

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3780.

ARVO Annual Meeting Abstract July 2019

Effects of Omidenepag, a Selective EP2 Receptor Agonist on Adipocyte Differentiation

Yasuko Yamamoto; Takazumi Taniguchi; Masahiro Ota; Ryo Iwamura; Kenji Yoneda; Noriko Odani-Kawabata; Takeshi Matsugi; Naveed Kamal Shams

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3781.

ARVO Annual Meeting Abstract July 2018

MUC5AC assay of extracts from Schirmer strips with human tear using a modified commercial ELISA kit

Naoto Mori; Hideki Miyake; Hidetoshi Mano; Takahiro Imanaka; Masatsugu Nakamura; Takeshi Matsugi; Naveed K Shams

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):4874.

ARVO Annual Meeting Abstract July 2018

Six-month efficacy and safety outcomes of a novel selective EP2 agonist omidenepag isopropyl: the RENGE study (Phase 3)

Makoto Aihara; Fenghe Lu; Hisashi Kawata; Akihiro Iwata; Noriko Odani-Kawabata; Naveed K Shams

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1229.

ARVO Annual Meeting Abstract July 2018

IOP lowering effect of omidenepag isopropyl in latanoprost non-/low-responder subjects with primary open-angle glaucoma or ocular hypertension: the FUJI study

Auli M Ropo; Makoto Aihara; Fenghe Lu; Hisashi Kawata; Akihiro Iwata; Noriko Odani-Kawabata; Naveed K Shams

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1233.

ARVO Annual Meeting Abstract July 2018

A Phase 3 trial comparing omidenepag isopropyl 0.002% with latanoprost 0.005% in primary open-angle glaucoma and ocular hypertension: the AYAME study

Fenghe Lu; Makoto Aihara; Hisashi Kawata; Akihiro Iwata; Noriko Odani-Kawabata; Naveed K Shams

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1235.

ARVO Annual Meeting Abstract July 2018

Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-induced Ocular Hypertensive Monkeys

Masahiro Fuwa; Carol B Toris; Shan Fan; Takazumi Taniguchi; Masaki Ichikawa; Noriko Odani-Kawabata; Ryo Iwamura; Kenji Yoneda; Takeshi Matsugi; Naveed Kamal Shams; Jin-Zhong Zhang

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):2717.

ARVO Annual Meeting Abstract July 2018

Effects of a selective EP2 receptor agonist, omidenepag isopropyl, on eyelash growth in mice

Yoshihiko Esaki; Osamu Katsuta; Takazumi Taniguchi; Ryo Iwamura; Kenji Yoneda; Noriko Odani-Kawabata; Mitsunori Maeda; Hidetoshi Mano; Takeshi Matsugi; Naveed Kamal Shams

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):2718.

Glaucoma January 2018

Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent

PDF

Tomoko Kirihara; Takazumi Taniguchi; Kenzo Yamamura; Ryo Iwamura; Kenji Yoneda; Noriko Odani-Kawabata; Atsushi Shimazaki; Takeshi Matsugi; Naveed Shams; Jin-Zhong Zhang
TAGS: agonists, antihypertensive agents, intraocular pressure, pharmacology, prostaglandins
Invest. Ophthalmol. Vis. Sci.. 2018; 59(1):145-153. https://doi.org/10.1167/iovs.17-22745

ARVO Annual Meeting Abstract June 2017

Pharmacokinetics, Safety and IOP Lowering Profiles of omidenepag isopropyl, a Selective EP2 Agonist in Healthy Japanese and Caucasian Volunteers (Phase I Study)

Makoto Aihara; Fenghe Lu; Hisashi Kawata; Yuki Tanaka; Kenzo Yamamura; Ryo Iwamura; Kenji Yoneda; Noriko Odani; Naveed Shams

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2104.

ARVO Annual Meeting Abstract June 2015

Safety and Efficacy of DE-117, a Selective EP 2 Agonist in a Phase 2a Study

Nnenna Ihekoromadu; Fenghe Lu; Ryo Iwamura; Kenji Yoneda; Noriko Kawabata-Odani; Naveed Kamal Shams

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5708.

ARVO Annual Meeting Abstract April 2014

The SAKURA Study, a Phase III, Multicenter, Randomized, Double-Masked, Study of Intravitreal Injections of DE-109 for the Treatment of Active, Noninfectious Uveitis of the Posterior Segment: Baseline Ocular Disease Characteristics

Pauline Merrill; Quan Dong Nguyen; W Lloyd Clark; Laura Wilson; Marye Ellen Valentine; Joel Naor; Naveed Shams; Afsheen Khwaja; Yang Yang; SAKURA Study Group

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):109.

ARVO Annual Meeting Abstract June 2013

12-Month Results of the SAVE Study - Sirolimus as Therapeutic Approach to UVEitis: A Randomized Study to Assess the Safety and Bioactivity of Intravitreal and Subconjunctival Injections of Sirolimus in Patients with Non-infectious Uveitis

Quan Dong Nguyen; Mohamed Ibrahim; Anthony Watters; Yasir Sepah; Millena Bittencourt; Jithin Yohannan; Joel Naor; Naveed Shams; Diana Do

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):5931.

ARVO Annual Meeting Abstract March 2012

An Exploration of the Relationships between Tear Osmolarity and Other Measures of Dry Eye Signs and Symptoms

Yang Yang; Marc Abrams; Will Garner; Michael Rinehart; Becky P. Senic; Hisao Shimada; Mukta Tripathi; Wei Liu; Naveed Shams

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):548.

ARVO Annual Meeting Abstract March 2012

Primary Endpoint Results Of The SAVE Study - Sirolimus As Therapeutic Approach To UVEItis: A Randomized Study To Assess The Safety And Bioactivity Of Intravitreal And Subconjunctival Injections Of Sirolimus In Patients With Non-infectious Uveitis

Quan Dong Nguyen; Mohamed Ibrahim; Anthony Watters; Millena Bittencourt; Jithin Yohannan; Yasir J. Sepah; Joel Naor; Naveed K. Shams; James P. Dunn; Diana V. Do

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):2251.

ARVO Annual Meeting Abstract April 2011

Sirolimus as Therapeutic Approach to Uveitis: A Randomized Study to Assess the Safety and Bioactivity of Intravitreal and Subconjunctival Injections of Sirolimus in Patients with Non-Infectious Uveitis (The Save Study)

Mohamed A. Ibrahim; Anthony Watters; Zubir Rentiya; Yasir J. Sepah; Henry A. Leder; Elham Hatef; Joel Naor; Naveed K. Shams; James P. Dunn; Quan D. Nguyen

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):4295.

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Safety and expression following subretinal administration of AAV.ABCA4.intein vectors in the non-human primate retina

Safety and Tolerability of Intravitreal Carotuximab (DE-122) in Patients With Persistent Exudative Age-Related Macular Degeneration: A Phase I Study

A randomized Phase 2 trial assessing the safety and efficacy of omidenepag isopropyl 0.002% once and twice daily in subjects with primary open-angle glaucoma or ocular hypertension (Spectrum 6)

Effects of Omidenepag Isopropyl, a Selective EP2 Receptor Agonist, on Iris Pigmentation

Effects of Omidenepag, a Selective EP2 Receptor Agonist on Adipocyte Differentiation

MUC5AC assay of extracts from Schirmer strips with human tear using a modified commercial ELISA kit

Six-month efficacy and safety outcomes of a novel selective EP2 agonist omidenepag isopropyl: the RENGE study (Phase 3)

IOP lowering effect of omidenepag isopropyl in latanoprost non-/low-responder subjects with primary open-angle glaucoma or ocular hypertension: the FUJI study

A Phase 3 trial comparing omidenepag isopropyl 0.002% with latanoprost 0.005% in primary open-angle glaucoma and ocular hypertension: the AYAME study

Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-induced Ocular Hypertensive Monkeys

Effects of a selective EP2 receptor agonist, omidenepag isopropyl, on eyelash growth in mice

Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent

Pharmacokinetics, Safety and IOP Lowering Profiles of omidenepag isopropyl, a Selective EP2 Agonist in Healthy Japanese and Caucasian Volunteers (Phase I Study)

Safety and Efficacy of DE-117, a Selective EP 2 Agonist in a Phase 2a Study

The SAKURA Study, a Phase III, Multicenter, Randomized, Double-Masked, Study of Intravitreal Injections of DE-109 for the Treatment of Active, Noninfectious Uveitis of the Posterior Segment: Baseline Ocular Disease Characteristics

12-Month Results of the SAVE Study - Sirolimus as Therapeutic Approach to UVEitis: A Randomized Study to Assess the Safety and Bioactivity of Intravitreal and Subconjunctival Injections of Sirolimus in Patients with Non-infectious Uveitis

An Exploration of the Relationships between Tear Osmolarity and Other Measures of Dry Eye Signs and Symptoms

Primary Endpoint Results Of The SAVE Study - Sirolimus As Therapeutic Approach To UVEItis: A Randomized Study To Assess The Safety And Bioactivity Of Intravitreal And Subconjunctival Injections Of Sirolimus In Patients With Non-infectious Uveitis

Sirolimus as Therapeutic Approach to Uveitis: A Randomized Study to Assess the Safety and Bioactivity of Intravitreal and Subconjunctival Injections of Sirolimus in Patients with Non-Infectious Uveitis (The Save Study)

To View More...

You must be signed into an individual account to use this feature.